About This Calculator

This Oncaspar (pegaspargase) Dosing Calculator provides a dose estimate for patients with Acute Lymphoblastic Leukemia (ALL). It determines the appropriate dose based on patient-specific parameters, including age, weight, and height, adhering to established clinical protocols for ALL treatment. The calculation method automatically adjusts based on the patient’s Body Surface Area (BSA), incorporating the dose cap specified in the FDA prescribing information.

Outputs Explained

Upon calculation, the tool provides a comprehensive summary of the dosing recommendation:

• Final Oncaspar (pegaspargase) Dose: The final recommended dose in International Units (IU), rounded to the nearest whole number.
• Dosing Method Used: Specifies whether the calculation was BSA-based (for patients with a BSA of 0.6 m² or greater) or weight-based (for patients with a BSA less than 0.6 m²).
• Calculation Breakdown: Shows the formula and values used to arrive at the uncapped dose (e.g., 2,500 IU/m² × 1.85 m²).
• Dose Cap Status: Indicates if the calculated dose exceeded the maximum single dose of 3,750 IU and was capped accordingly.

How to Use the Calculator

To ensure an accurate dose calculation, please follow these steps:

• Patient Age: Enter the patient’s age in years.
• Prescribed Dose per m²: The tool defaults to 2,500 IU/m², a standard dose. Adjust only if a different protocol is being followed.
• Patient Weight: Enter the patient’s weight and select the correct unit (kg or lbs).
• Patient Height: Enter the patient’s height and select the correct unit (cm or in).
• Calculate: Click the “Calculate Dose” button to see the results. All calculations must be independently verified by a qualified healthcare professional.

Dosing Overview

Oncaspar dosing for ALL is administered every 14 days and is stratified based on Body Surface Area (BSA), which the tool calculates using the Mosteller formula.

• Patients with BSA ≥ 0.6 m²: The standard dose is 2,500 IU/m² administered intravenously (IV) or intramuscularly (IM).
• Patients with BSA < 0.6 m²: The dose is calculated based on weight at 82.5 IU/kg administered IV or IM.
• Maximum Dose: Regardless of BSA or weight, the maximum recommended single dose of Oncaspar is 3,750 IU. The calculator automatically applies this cap if the calculated dose exceeds this limit.

For IM administration, the volume per injection site should not exceed 2 mL. If the calculated volume is larger, the dose should be divided and administered in multiple sites.

Switching from Asparaginase

When substituting Oncaspar for asparaginase Erwinia chrysanthemi, the recommended dosage is 2,500 IU/m² administered IM or IV every 14 days. This substitution is typically done for patients who have had a hypersensitivity reaction to native E. coli-derived asparaginase.

Missed Dose

If a planned dose of Oncaspar is missed, it should be administered as soon as possible. The subsequent dosing schedule should be adjusted to maintain a 14-day interval between doses. It is critical to consult the treating oncologist or institutional protocol for specific guidance on managing a missed dose.

Safety Alerts

Frequently Asked Questions

• Why did the calculator use a weight-based dose instead of a BSA-based one?
  A weight-based dose (82.5 IU/kg) is used when the patient’s calculated BSA is less than 0.6 m², as per prescribing guidelines.
• What is the maximum dose of Oncaspar?
  The maximum single dose is 3,750 IU. The calculator will cap any dose calculated above this value.
• What BSA formula does the calculator use?
  The tool uses the Mosteller formula: BSA (m²) = √([Height(cm) × Weight(kg)] / 3600).
• Can I use this calculator for other forms of asparaginase?
  No. This tool is specifically calibrated for Oncaspar (pegaspargase) and its unique dosing regimen.
• Does this tool account for dose modifications for toxicity?
  No. This calculator determines the initial, standard dose. Dose adjustments due to toxicity or adverse events must be made by the treating clinician based on clinical judgment and institutional protocols.
• Why is the default prescribed dose set to 2,500 IU/m²?
  This is the standard, FDA-approved dose for Oncaspar as a component of multi-agent chemotherapy for patients with ALL.
• Can Oncaspar be self-administered?
  No. Oncaspar must be administered by a qualified healthcare professional in a clinical setting equipped to manage potential hypersensitivity reactions.
• How often is Oncaspar given?
  The standard dosing schedule is one dose every 14 days.

References

• ONCASPAR® (pegaspargase) Prescribing Information. Servier Pharmaceuticals LLC. FDA.gov.
• ONCASPAR® HCP Website. Servier Pharmaceuticals. Oncaspar.com.
• Drugs@FDA: ONCASPAR (pegaspargase). FDA.gov.
• van der Sluis IM, et al. Consensus-based recommendations for the management of asparaginase-associated toxicities in children and young adults. Haematologica. 2016. PMC5013959.